KR20080109116A - Beverage for relieving hangover and manufacturing method thereof - Google Patents
Beverage for relieving hangover and manufacturing method thereof Download PDFInfo
- Publication number
- KR20080109116A KR20080109116A KR1020070057015A KR20070057015A KR20080109116A KR 20080109116 A KR20080109116 A KR 20080109116A KR 1020070057015 A KR1020070057015 A KR 1020070057015A KR 20070057015 A KR20070057015 A KR 20070057015A KR 20080109116 A KR20080109116 A KR 20080109116A
- Authority
- KR
- South Korea
- Prior art keywords
- activity
- hangover
- extract
- alcohol
- adh
- Prior art date
Links
- 206010019133 Hangover Diseases 0.000 title claims abstract description 47
- 235000013361 beverage Nutrition 0.000 title claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 51
- 239000000284 extract Substances 0.000 claims abstract description 42
- 235000019441 ethanol Nutrition 0.000 claims abstract description 31
- 240000000643 Alnus japonica Species 0.000 claims abstract description 5
- 241000555678 Citrus unshiu Species 0.000 claims abstract description 5
- 240000008917 Glycyrrhiza uralensis Species 0.000 claims abstract description 5
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 claims abstract description 5
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 5
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 5
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 5
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 241000675108 Citrus tangerina Species 0.000 claims description 15
- 241000202807 Glycyrrhiza Species 0.000 claims description 15
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 15
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 15
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 15
- 229940010454 licorice Drugs 0.000 claims description 15
- 241000411851 herbal medicine Species 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000012676 herbal extract Substances 0.000 claims description 3
- 235000012907 honey Nutrition 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000004745 nonwoven fabric Substances 0.000 claims description 2
- 229920001542 oligosaccharide Polymers 0.000 claims description 2
- 150000002482 oligosaccharides Chemical class 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 abstract description 38
- 108010021809 Alcohol dehydrogenase Proteins 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 37
- 230000002401 inhibitory effect Effects 0.000 abstract description 29
- 210000004185 liver Anatomy 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 abstract description 6
- 102000004190 Enzymes Human genes 0.000 abstract description 5
- 108090000790 Enzymes Proteins 0.000 abstract description 5
- 241000207199 Citrus Species 0.000 abstract description 2
- 235000020971 citrus fruits Nutrition 0.000 abstract description 2
- 241000628997 Flos Species 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 description 43
- 230000003078 antioxidant effect Effects 0.000 description 20
- 241000894006 Bacteria Species 0.000 description 18
- 230000009036 growth inhibition Effects 0.000 description 17
- 239000000523 sample Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 239000002023 wood Substances 0.000 description 13
- 241000700159 Rattus Species 0.000 description 12
- 239000000052 vinegar Substances 0.000 description 12
- 235000021419 vinegar Nutrition 0.000 description 12
- 241000219495 Betulaceae Species 0.000 description 11
- 208000004232 Enteritis Diseases 0.000 description 10
- 241000607598 Vibrio Species 0.000 description 10
- 239000001974 tryptic soy broth Substances 0.000 description 10
- 108010050327 trypticase-soy broth Proteins 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 241000192125 Firmicutes Species 0.000 description 7
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 235000014469 Bacillus subtilis Nutrition 0.000 description 6
- 241000588724 Escherichia coli Species 0.000 description 6
- 101000744515 Homo sapiens Ras-related protein M-Ras Proteins 0.000 description 6
- 241000191938 Micrococcus luteus Species 0.000 description 6
- 102100039789 Ras-related protein M-Ras Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 235000008216 herbs Nutrition 0.000 description 5
- 208000019423 liver disease Diseases 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 4
- 240000004371 Panax ginseng Species 0.000 description 4
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000035622 drinking Effects 0.000 description 4
- 239000000469 ethanolic extract Substances 0.000 description 4
- 235000008434 ginseng Nutrition 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229940069445 licorice extract Drugs 0.000 description 4
- 229960003085 meticillin Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 241000556533 uncultured marine bacterium Species 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- 235000004835 α-tocopherol Nutrition 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 241000195493 Cryptophyta Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- -1 dydzein Chemical compound 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 3
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 3
- 229960004949 glycyrrhizic acid Drugs 0.000 description 3
- 235000019410 glycyrrhizin Nutrition 0.000 description 3
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000219496 Alnus Species 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000588915 Klebsiella aerogenes Species 0.000 description 2
- 241000629562 Klebsiella aerogenes KCTC 2190 Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 230000002292 Radical scavenging effect Effects 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229910052733 gallium Inorganic materials 0.000 description 2
- 208000001130 gallstones Diseases 0.000 description 2
- PSFDQSOCUJVVGF-UHFFFAOYSA-N harman Chemical compound C12=CC=CC=C2NC2=C1C=CN=C2C PSFDQSOCUJVVGF-UHFFFAOYSA-N 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000000401 methanolic extract Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000015961 tonic Nutrition 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- QGJZLNKBHJESQX-UHFFFAOYSA-N 3-Epi-Betulin-Saeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(=C)C)C5C4CCC3C21C QGJZLNKBHJESQX-UHFFFAOYSA-N 0.000 description 1
- CLOUCVRNYSHRCF-UHFFFAOYSA-N 3beta-Hydroxy-20(29)-Lupen-3,27-oic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C(O)=O)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C CLOUCVRNYSHRCF-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 206010001623 Alcoholic hangover Diseases 0.000 description 1
- 235000006576 Althaea officinalis Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical compound OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- DIZWSDNSTNAYHK-XGWVBXMLSA-N Betulinic acid Natural products CC(=C)[C@@H]1C[C@H]([C@H]2CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12)C(=O)O DIZWSDNSTNAYHK-XGWVBXMLSA-N 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000605411 Lloydia Species 0.000 description 1
- RCQBVCISWCRYBO-SOYDKUNTSA-N Lupenone Natural products CC(=C)[C@@H]1CC[C@]2(C)CC[C@@H]3[C@H](CC[C@H]4[C@@]3(C)CC[C@H]5C(C)(C)C(=O)CC[C@]45C)[C@@H]12 RCQBVCISWCRYBO-SOYDKUNTSA-N 0.000 description 1
- GRBHNQFQFHLCHO-UHFFFAOYSA-N Lupenonq Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C GRBHNQFQFHLCHO-UHFFFAOYSA-N 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 244000136948 Ocimum sanctum Species 0.000 description 1
- 235000004072 Ocimum sanctum Nutrition 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000283903 Ovis aries Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000003141 Plant Poisoning Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 241001327284 Sorghastrum nutans Species 0.000 description 1
- 241000192085 Staphylococcus gallinarum Species 0.000 description 1
- BHTRKEVKTKCXOH-UHFFFAOYSA-N Taurochenodesoxycholsaeure Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)CC2 BHTRKEVKTKCXOH-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- QGJZLNKBHJESQX-FZFNOLFKSA-N betulinic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C QGJZLNKBHJESQX-FZFNOLFKSA-N 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019987 cider Nutrition 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 244000038559 crop plants Species 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- PZXJOHSZQAEJFE-UHFFFAOYSA-N dihydrobetulinic acid Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C(C)C)C5C4CCC3C21C PZXJOHSZQAEJFE-UHFFFAOYSA-N 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- OLWSWWUSGLHFEB-UHFFFAOYSA-N glutinol Natural products CC1C(O)CCC2C1=CCC3C2(C)CCC4(C)C5CC(C)(C)CCC5(C)CCC34C OLWSWWUSGLHFEB-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- GRBHNQFQFHLCHO-BHMAJAPKSA-N lupenone Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C GRBHNQFQFHLCHO-BHMAJAPKSA-N 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- MQYXUWHLBZFQQO-UHFFFAOYSA-N nepehinol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=C)C)C5C4CCC3C21C MQYXUWHLBZFQQO-UHFFFAOYSA-N 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000011251 protective drug Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 230000011273 social behavior Effects 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- BHTRKEVKTKCXOH-LBSADWJPSA-N tauroursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)CC1 BHTRKEVKTKCXOH-LBSADWJPSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 241000215338 unidentified plant Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/68—Acidifying substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/70—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter
- A23L2/72—Clarifying or fining of non-alcoholic beverages; Removing unwanted matter by filtration
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
- A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
- A23L21/25—Honey; Honey substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/032—Citric acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/28—Oligosaccharides
Abstract
Description
도 1은 지구병 추출물의 항균활성 시험결과를 보인 사진이고,Figure 1 is a photograph showing the antimicrobial activity test results of the Earth disease extract,
도 2는 갈화 추출물의 항균활성 시험결과를 보인 사진이고,Figure 2 is a photograph showing the antimicrobial activity test results of gallium extract,
도 3은 목초액의 항균활성 시험결과를 보인 사진이다.Figure 3 is a photograph showing the antimicrobial activity test results of wood vinegar.
본 발명은 숙취해소용 음료 및 이의 제조방법에 관한 것으로서, 보다 상세하게는 생약추출물을 원료로 하는 숙취해소용 음료 및 이의 제조방법에 관한 것이다.The present invention relates to a hangover drink and a method for producing the same, and more particularly to a hangover drink and a method for producing the hangover extract as a raw material.
경제성장과 평균수명의 연장과 함께 현대인들의 질병과 고령화 사회에 따른 삶의 질에 대한 인식이 변하고 있으며, 그에 따른 항산화, 항균, 항암 및 면역 강화활성 등의 생리활성을 갖는 천연물에 대한 관심이 높아가고 있다(Das et al., 2002: Lee and Lee; Park and Kim, 1992).Along with the economic growth and the extension of life expectancy, the perception of modern people's quality of life due to disease and aging society is changing, and there is a great interest in natural products with physiological activities such as antioxidant, antibacterial, anticancer and immune enhancing activities. (Das et al., 2002: Lee and Lee; Park and Kim, 1992).
음료에 대한 기호성도 변화하여 단순히 청량감을 주는 콜라, 사이다의 소비는 줄어들고, 차츰 천연물을 주원료로 한 제품의 판매량이 매년 증가되고 있 다(Park et al., 1998). 또한 최근에는 건강에 관한 관심이 고조되면서 질병 치료를 위한 약물의 본래 성분인 약리학적 성분을 살리면서도 기능성을 함유한 건강음료가 개발되고 있다. 이에 재료로서 채소류 및 한약재 등 천연성분을 주로 이용하는 추세이다(Seo and Kim, 2001). 이러한 맥락에서 숙취해소음료의 개발 역시 활발히 진행 중이다.The palatability of beverages is also changing, and the consumption of cola and cider, which is simply refreshing, is decreasing, and the sales volume of products mainly made from natural products is increasing every year (Park et al., 1998). In recent years, as health concerns are heightened, health drinks containing functionalities while developing pharmacological components, which are inherent components of drugs for treating diseases, have been developed. As a result, natural ingredients such as vegetables and herbs are mainly used (Seo and Kim, 2001). In this context, the development of hangover drinks is also active.
술은 태초부터 인류에게 전해내려온 산물이며, 음주는 인간이 가지고 있는 여러가지 사회적 습관들 중 비교적 지속성을 가지고 있는 사회적 행동이다(Health, 1990). 알코올은 뇌의 중추신경에 작용하여 기분을 좋게 하고, 괴로움을 잊을 수 있어 고대에는 알코올이 모든 약물의 기본 부형제로 이용되었다(Marshall and Fritz, 1989).Alcohol is a product that has been handed down to mankind since the beginning, and drinking is a social behavior that is relatively persistent among various social habits (Health, 1990). Alcohol acts on the central nervous system of the brain to make you feel better and to forget the pain, so in ancient times alcohol was used as the primary excipient for all drugs (Marshall and Fritz, 1989).
알코올은 섭취시 체내에 흡수되어 전신에 고루 분포되며, 대부분은 간에서 알코올 탈수소효소(alcohol dehydrogenase: ADH), 아세트알데히드 탈수소효소(acetaldehyde dehydrogenase: ALDH), 소포제(endoplasmic reticulum) 내의 알코올 산화계(microsomal ethanol oxidizing system: MEOS), 카타라제(catalase) 및 과산화효소(peroxidase) 등 특정한 효소들에 의해서 대사되고, 흡수된 알코올의 10% 미만은 대사되지 않은 채 신장이나 폐를 통하여 배설된다.Alcohol is absorbed into the body at the time of ingestion and is distributed evenly throughout the body, and most of the alcohol in the liver, alcohol dehydrogenase (ADH), acetaldehyde dehydrogenase (ALLDH), endoplasmic reticulum (microsomal ethanol) It is metabolized by certain enzymes such as oxidizing system (MEOS), catalase and peroxidase, and less than 10% of the absorbed alcohol is excreted through the kidneys or lungs without being metabolized.
하지만, 알코올의 다량섭취로 인한 급성 알코올성 숙취증상인 메스꺼움, 구토, 현기증, 갈증, 무기력, 두통, 근육통 등의 증상은 업무능률 저하로 인한 사회 경제적 손해를 초래하고 있으며(Swift and Davidson, 1998), 만성적인 알코올 섭취 시에는 췌장염, 심근경색, 신경장애, 결핵 등의 장해가 나타나고 간 조직의 구조 및 기능에 치명적인 손상을 가져오게 된다(Lieber and Leo, 1992; Liever et al., 1986). 그러므로 채내의 다른 장기에 비하여 알코올이 간에 미치는 영향은 매우 크다고 볼 수 있다(Goodman and Gilman, 1975; Lieber and DeCarli, 1968; Lieber et al., 1986).However, symptoms such as nausea, vomiting, dizziness, thirst, lethargy, headache, and muscle pain, such as acute alcoholic hangover symptoms caused by high intake of alcohol, cause socioeconomic damage due to decreased work efficiency (Swift and Davidson, 1998), Chronic alcohol intake causes disorders such as pancreatitis, myocardial infarction, neuropathy, and tuberculosis, and can lead to fatal damage to the structure and function of liver tissue (Lieber and Leo, 1992; Liever et al., 1986). Therefore, the effect of alcohol on the liver is very large compared to other organs in the mine (Goodman and Gilman, 1975; Lieber and DeCarli, 1968; Lieber et al., 1986).
현재 우리나라의 음주문화의 특성으로 나타나는 과음 또는 빈번한 음주로 유발되는 간 기능 장애는 날로 증가하는 추세에 있으며, 이로 말미암아 나타나는 여러 가지 간질환의 예방 및 치유는 중요한 연구과제 중의 하나로 주목받고 있으며 많은 사람들이 숙취를 제거할 수 있는 약물 또는 음료수에 많은 관심을 기울이고 있다. Currently, the liver dysfunction caused by excessive drinking or frequent drinking, which is a characteristic of Korean drinking culture, is increasing day by day. Therefore, prevention and healing of various liver diseases appearing as one of the important research tasks, Much attention is paid to drugs or beverages that can eliminate hangovers.
또한, 숙취 제거와 관련하여, 천연 식품 또는 한약 재료로부터 추출한 성분을 함유한 다양한 건강 보조 식품이 개발되고 있다(김정한 등, 한국농화학회지, 38(6): 549-553, 1995). 이러한 연구의 일환으로서, 이담 작용, 간장 해독, 간혈류 개선 작용, 지방의 흡수 촉진 작용 및 미세 담도를 통한 노폐물 배설 작용을 하는 콜린산류를 함유하는 조성물이 시판되고 있다.In addition, in connection with the elimination of hangovers, various dietary supplements containing ingredients extracted from natural foods or herbal medicines have been developed (Kim Jung-han et al., 38 (6): 549-553, 1995). As part of this research, a composition containing choline acids, which have an effect of edema, hepatic detoxification, hepatic blood flow improvement, promoting fat absorption, and excretion of waste products through fine bile ducts, is commercially available.
이러한 콜린산의 예로서 간질환의 간 기능 개선, 간 기능 장애에 의한 전신 권태, 소화 불량, 식욕 부진, 육체 피로 등에 효과가 있다고 알려져 있는 우루소데옥시콜린산(ursodeoxycholic acid); 담석 용해제로 시판되고 있으며, 지방간 치료에 효과가 있어 경구 투여시 간 기능 개선 및 간 지방량 감소의 효과가 있는 타우로우루소데옥시콜린산(tauroursodeoxycholic acid); 담석 용해제로 시판되고 있는 체노데옥시콜린산(chenodeoxycholic acid); 및 디하이드로콜린 산(dehydrocholicacid) 등이 있다. Examples of such choline acid include ursodeoxycholic acid, which is known to be effective in improving liver function of liver disease, systemic malaise due to liver dysfunction, indigestion, anorexia, physical fatigue, and the like; Tauroursodeoxycholic acid, which is commercially available as a gallstone dissolving agent and is effective in treating fatty liver, which has an effect of improving liver function and reducing liver fat mass when orally administered; Chenodeoxycholic acid sold as a gallstone dissolving agent; And dehydrocholic acid.
한편, 한약재 또는 민간요법제로서 숙취해소에 유용한 효과가 있다고 알려져 있는 인삼, 가시오가피 등의 성분을 주성분으로 하는 각종 제제 형태의 의약품들이 개발되었다. 이 중에서, 인삼을 주성분으로 하는 자양 강장 드링크제가 다수 시판되고 있으며, 이 외에도, 꿀, 비타민 등의 각종 성분들도 적당량의 함량으로 조성하여 자양강장제로 시판되고 있다. 인삼, 가시오가피 (Brekhman et al., Lloydia , 32(1): 46-51, 1969), 오씨뭄 (Ocimum sanctum Linn), 티노스포라말라바리카 (tinosporama labarica) (Sen, P., Maiti, PC and Ray, A. Indian J. Exp. Biol., 30: 592-596, 1992)등의 생약과 멜라토닌 등의 생체 물질이 숙취 해소 작용을 나타낸다고 하는 보고되어 있으나, 이들 재료들은 음주에 의해 유발되는 다양한 숙취 증상 중에서 일부 증상에만 효과가 있거나, 숙취 해소 효과가 미미한 것으로 나타났다. On the other hand, as a herbal medicine or folk remedies, various types of medicines have been developed, which are mainly composed of ingredients such as ginseng and thorny ginseng, which are known to have a beneficial effect on hangover. Among them, a number of nourishing tonic drinks are mainly marketed as ginseng, and in addition, various components such as honey and vitamins are also formulated in an appropriate amount and marketed as nourishing tonics. Ginseng, Brykhman et al., Lloydia, 32 (1): 46-51, 1969, Ocimum sanctum Linn, tinosporama labarica (Sen, P., Maiti, PC and Ray, A. Indian J. Exp. Biol., 30: 592-596, 1992), and herbal substances such as melatonin and other biological substances have been reported to exhibit hangover remedy. Among the symptoms, only some symptoms were effective, or the hangover effect was found to be insignificant.
최근에 콩나물을 주원료로 한 식물 엑기스를 함유한 제품과 미배아와 대두 추출물을 함유한 제품이 소개되고 있다. 그러나, 이들 역시 제제의 안정성 면에서 여전히 해결해야 할 많은 문제점이 지적되었다.Recently, a product containing a plant extract mainly containing bean sprouts and a product containing a germ and soybean extract have been introduced. However, these also pointed out many problems that still need to be solved in terms of the stability of the formulation.
따라서, 이 분야에서 이러한 문제점을 해결하기 위하여 숙취해소에 효과가 있으면서도 안정성이 확보된 새로운 숙취 제거용 조성물의 개발이 요구되고 있다.Therefore, in order to solve this problem in the field, there is a demand for the development of a new hangover removal composition having an effect on the hangover while ensuring stability.
본원발명은 상기와 같은 종래기술의 문제점을 해결하기 위하여 마련된 것으로서, 생약재료를 사용하여, 발명은 간에서 알코올을 대사하는 일차효소인 알코올 탈수소효소의 활성을 저해함으로써 알코올의 산화물질인 아세트알데히드의 생성을 억제시키며, 이에 따라 간 보호 효과 또는 숙취현상을 억제할 수 있는 숙취해소용 음료 및 이의 제조방법을 제공하는 것을 목적으로 한다.The present invention has been made to solve the problems of the prior art as described above, by using a herbal material, the invention inhibits the activity of alcohol dehydrogenase which is the primary enzyme metabolizing alcohol in the liver of the acetaldehyde which is an oxide of alcohol It is an object of the present invention to provide a hangover-relieving beverage and a method for producing the same, which can suppress the production and thereby suppress the liver protection effect or the hangover phenomenon.
상기 목적을 달성하기 위하여, 본원 발명은 오리목(Alnus japonica), 귤피(Citrus unshiu), 감초(Glycyrrhiza uralensis), 지구병(Hovenia dulcis) 및 갈화(Pueraria thunbergiana)를 에틸알코올로 추출한 추출액을 유효성분으로 하는 것을 특징으로 하는 숙취해소용 음료 조성물을 제공한다.In order to achieve the above object, the present invention is an active ingredient extracted from the alder tree (Alnus japonica), citrus (Citrus unshiu), licorice (Glycyrrhiza uralensis), Earth disease (Hovenia dulcis) and brown (Pueraria thunbergiana) as an active ingredient It provides a drink composition for hangover relief characterized in that.
이하, 본 발명에 대해 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 숙취해소용 음료에 포함되는 감초(甘草, Glycyrrhiza uralensis) 추출물은 이미 한약재료로서 익히 알려져 널리 사용되는 유용한 식물로서, 트리터펜(triterpene)계 사포닌, 글리시리진(Glycyrrhizin), 리퀴리틴(Liquirition), 아스파라긴(Asparagin), 글루탐산(Glutamic acid), 포도당 등을 함유하고 있다. 글리시리진산의 2-글루쿠론(glucuron)산 배당체로 감초의 감미 성분인 글리시리진은 약물중독, 식물중독, 체내대사물의 중독뿐만 아니라 세균 소독 등에 대한 다양한 해독작용이 있어 간에서의 해독작용을 돕는다고 알려져 있다.Licorice (甘草, Glycyrrhiza uralensis) extract contained in the hangover drink of the present invention is a useful plant that is well known and widely used as a herbal medicine, triterpene-based saponins, glycyrrhizin, Glycyrrhizin, Liquirition (Liquirition) ), Asparagin, Glutamic Acid, Glucose, etc. 2-glucuronic acid glycoside of glycyrrhizic acid is a sweetener component of licorice and is known to help detoxification in liver because it has various detoxification effects for drug poisoning, plant poisoning, poisoning of body metabolism as well as bactericidal disinfection. have.
본 발명의 숙취해소용 음료에 포함되는 갈화(Pueraria thunbergiana) 추출 물에는 로비닌, 게니스테인, 이소플라본, 다이드제인, 쿠에르세틴 등의 플라보노이드와 정유성분 및 안식향산, 프로피온산, 쿠마르산 등이 포함되어 있다. 이중 로비닌은 이뇨 작용과 혈중 잔여 질소 함량 감소 효과를 가져 주독 해독 작용과 주로 관계가 있는 것으로 알려져 있으며, 다이드제인은 편두통, 고혈압, 협심증 등 여러 가지 심장의 대상기능 부전증에 작용하는 것으로 알려져 있다.The extract of Pueraria thunbergiana included in the hangover drink of the present invention includes flavonoids, essential oils and benzoic acid, benzoic acid, propionic acid, coumaric acid, and the like, such as rovinin, genistein, isoflavone, dydzein, and quercetin. It is. Rovinin has been known to be mainly related to detoxification due to diuretic effect and reduction of residual nitrogen content in blood, and Dyzedine is known to act on various heart failures such as migraine, hypertension and angina. .
본 발명의 숙취해소용 음료에 포함되는 오리목(Alnus japonica)은 자작나무과(Betulaceae)에 속하며 한자로는 유리목(楡理木)이라고도 하고, 중국은 차조(茶條)라 했다. 오리나무의 어린 지엽 및 수피를 적양이라고 하며, 봄, 가을이 채취하여 햇볕에 건조하여 사용한다. 그 주요성분으로는 루페논(lupenone), 베타-아밀린(β-amylin), 글루테놀(glutenol), 타락세롤(taraxerol), 베투리닉산(betulinic acid) 등 다량의 트리터페노이드(triterpenoid) 외에 베타-시토스테롤(β-sitosterol), 지방족 알콜, 파이로카테콜(pyrocatechol) 계 탄닌(tannin)이 함유되어 있다. 그 효능에는 화상, 외상출혈을 진정시키고, 청열, 강화의 효능이 있는 것으로 알려져 있다.Alnus japonica included in the hangover drink of the present invention belongs to the birch family (Betulaceae) and is also known as Yurimok (楡 理 木) in Chinese, and is called Chajo (茶 條). The young leaves and bark of alder trees are called red lambs. Spring and autumn are collected and dried in the sun. Its main ingredients include large amounts of triterpenoids such as lupenone, beta-amylin, glutenol, taraxerol, and betulinic acid. Β-sitosterol, fatty alcohols, pyrocatechol-based tannins are contained. Its effects are known to soothe burns and traumatic bleeding, and to clear and strengthen.
본 발명의 숙취해소용 음료에 포함되는 귤피(Citrus unshiu)는 우리가 흔히 볼 수 있는 귤의 껍질만 따로 채집하여 건조시킨 것으로 진피라고도 한다. 상기 귤피는 기가 뭉친 것을 풀어주고 비장의 기능을 강화하며 습을 제거하는 동시에 담을 삭히는 효능이 있다. 또한, 상기 귤피는 아스쿨린, 아스쿨레틴, 탄닌 등을 함유 하고 있으며, 해소, 천식, 진해, 거담에 효과가 있고, 소염진통, 요량 및 요산의 배출을 도와주어 알콜의 체내배출이 신속하게 이루어지도록 한다.Tangerine blood (Citrus unshiu) included in the hangover drink of the present invention is collected by drying only the peel of tangerine as commonly seen by us and is also called dermis. The tangerine is effective in releasing clumps, strengthening the function of the spleen, removing moisture, and at the same time scavenging the walls. In addition, the tangerine contains aspirin, askulete, tannin, etc., is effective in relieving, asthma, antitussive, expectoration, anti-inflammatory pain, urine and uric acid to help the discharge of alcohol in the body quickly To be done.
본 발명의 숙취해소용 음료에 포함되는 지구병(Hovenia dulcis)은 헛개 나무라고도 하며, 사과산, 포도당, 칼슘, 하벤산, 후랑크리닌, 호베닌, 호베노시드을 함유하고 있으며, 술해독 작용이 뛰어난 것으로 알려져 있다. 특히, 상기 지구병의 열매인 지구자는 과당, 포도당, 카탈라제, 페록시다아제, 칼륨, 칼슘, 철, 트리테르페노이드인, 호베인산, 루틴, 사포닌, 압페롭신 등이 호간기능 회복과 숙취해소 및 간독성 해소효과가 뛰어난 것으로 알려져 있다.Earth disease (Hovenia dulcis) included in the hangover drink of the present invention is also known as a hut tree, contains malic acid, glucose, calcium, habenic acid, furclinine, hobenin, hobenoside, and is excellent in alcohol detoxification Known. In particular, the earth fruit, the fruit of the earth disease, fructose, glucose, catalase, peroxidase, potassium, calcium, iron, triterpenoids, hobeic acid, rutin, saponin, apelopsin, etc. It is known to be effective in relieving and relieving liver toxicity.
본 발명은 특히, 상기한 원료들의 추출물을 모두 함유하는 것을 특징으로 한다. 본 발명을 하기의 실시예에 의해서 상세히 설명할 것이나, 이들 실시예는 본 발명을 예시하기 위한 것일 뿐이며, 본 발명의 범위가 이들 실시예에 의하여 한정되는 것은 아니다.In particular, the present invention is characterized by containing all the extract of the above-described raw materials. The present invention will be described in detail by the following examples, but these examples are only for illustrating the present invention, and the scope of the present invention is not limited to these examples.
제조예Production Example : 추출물의 제조: Preparation of Extract
감초, 갈화, 오리목, 귤피 및 지구병 각각의 건조 생약재 600g에 10배에 해당되는 40% 에틸알콜(pretanol A)(95% 주정 알코올: 증류수 = 2:3) 6,000㎖을 가하여 약탕기(무압력 원심분리순환식, 미강기업)로 120분간 추출하였다. 추출된 물질을 부직포로 여과한 후, 회전식 감압 농축기(Rotary Vacuum Evaporator)(Eyela N-1000, Japan)로 1,000㎖까지 감압 농축하여 원심분리(10,000×g, 40min, 4℃)하였다. 이때 얻어진 상층액의 1/10씩 나누어서 동결 건조하였고, 4℃에 보관하였다. 또한 실험에 사용된 생약재들에 대한 추출수율의 측정은 생약재 600g에 대한 추출물의 총 가용성 고체 함량의 백분비로 표 1에 표시하였다.600g of dry herbs of licorice, brownish, alder, tangerine, and earth diseases are added with 6,000ml of 40% ethyl alcohol A (95% alcohol: distilled water = 2: 3), which is 10 times higher. Extraction cycle, rice bran company) was extracted for 120 minutes. The extracted material was filtered through a nonwoven fabric, and then concentrated under reduced pressure to 1,000 ml using a rotary vacuum evaporator (Eyela N-1000, Japan) and centrifuged (10,000 × g, 40 min, 4 ° C.). The supernatant obtained at this time was divided by 1/10 and lyophilized and stored at 4 ° C. In addition, the measurement of the extraction yield for the herbal medicines used in the experiment is shown in Table 1 as a percentage of the total soluble solids content of the extract for 600g herbal medicines.
표 1. 40% 에틸알콜에 의한 각각의 시험 식물의 추출 수율Table 1. Extraction yield of each test plant with 40% ethyl alcohol
실시예Example 1 및 1 and 비교예Comparative example 1 내지 3: 추출물의 제조 및 구입 1 to 3: Preparation and purchase of extract
본 실험에서 제조한 숙취해소음료 조성물은 표1에 나타낸 한약재와 목초액을 주원료로 배합하여 생약재를 추출한 방법과 동일한 추출용매를 사용하여 추출하였으며, 이외 벌꿀, 올리고당, 구연산을 미량 첨가하여 조제하여 해주가(Haejuga)로 명명하였다. 또한 본 발명의 숙취해소음료 조성물과 기존에 판매되고 있는 숙취해소음료와의 비교를 위하여 A, B, C사에서 판매중인 숙취해소음료를 각각 시중에서 구입하여 실험에 사용하였다.The hangover beverage composition prepared in this experiment was extracted using the same extraction solvent as the method of extracting the herbal medicine by combining the herbal medicine and wood vinegar solution shown in Table 1 as the main ingredients, and prepared by adding a small amount of honey, oligosaccharide and citric acid. (Haejuga). In addition, for the comparison between the hangover drink composition of the present invention and the hangover drink sold in the past, the hangover drink sold by A, B, C companies were purchased in the market and used in the experiment.
시험예1Test Example 1 : 알코올 탈수소효소 활성의 측정: Determination of Alcohol Dehydrogenase Activity
1. 실험방법1. Experimental method
1) 이스트 ADH(yeast ADH) 활성의 측정1) Determination of yeast ADH activity
이스트 ADH(Sigma Co., St. Louis, MO, USA)의 활성도는 이전의 연구방법(Jung et al.,)을 변형하여 UV 분광광도계(UV spectrophotometer)를 이용하여 340㎚에서 형성되는 NADH의 흡광도를 다음과 같이 측정하였다. 40unit/㎖ ADH, 13mM NAD+ 유리산(Sigma Co., St. Louis, MO, USA)는 조제 후 -20℃에서 보관하면서 사용하였으며, 트리스-베이스(tris-base)(Sigma Co., St. Louis, MO, USA)로 만든 0.05 M 트리스-완충액(pH 8.8)는 4℃에서 보관하면서 사용하였다(Kim and Zeikus, 1992)The activity of yeast ADH (Sigma Co., St. Louis, MO, USA) was modified by the previous method (Jung et al.,) And absorbance of NADH formed at 340 nm using a UV spectrophotometer. Was measured as follows. 40 units / ml ADH, 13 mM NAD + free acid (Sigma Co., St. Louis, Mo., USA) was used after storage at −20 ° C., tris-base (Sigma Co., St. Louis, MO, USA), 0.05 M Tris-buffer (pH 8.8) was used while stored at 4 ° C. (Kim and Zeikus, 1992)
UV 큐베트(UV cuvette)에 ADH 0.008㎖, 에탄올 0.04㎖, NAD 0.08㎖를 넣어 총 부피가 1㎖가 되도록 0.05M 트리스 버퍼를 넣어 대조시험을 하였다. 추출물 시료에 대한 ADH의 저해 또는 활성화를 보기 위하여 50㎎ 생약추출물을 1㎖ 증류수에 현탁하여 원심분리하고 상등액 10㎕를 효소 반응액에 가하였으며, 본 연구에서 조제한 숙취 음료 및 비교를 위한 타회사 숙취음료 A, B, C는 45㎕의 농도로 첨가하여 효소활성을 측정하였다. ADH의 활성은 대조 시험에서 나타낸 ADH의 활성에 대하여 추출물 또는 숙취해소음료를 첨가하였을 때의 ADH의 활성을 나타내는 상대적인 ADH활성도(%)를 구하였다.In a UV cuvette, 0.05M Tris buffer was added to 0.008ml of ADH, 0.04ml of ethanol, and 0.08ml of NAD to make a total volume of 1ml. 50 mg herbal extracts were suspended in 1 ml distilled water and centrifuged in order to see the inhibition or activation of ADH on the extract samples. 10 μl of the supernatant was added to the enzyme reaction solution. Beverages A, B, and C were added at a concentration of 45 μl to measure the enzyme activity. The activity of ADH was calculated for the relative ADH activity (%) indicating the activity of ADH when the extract or hangover beverage was added to the activity of ADH indicated in the control test.
2) 쥐간(rat liver) ADH 활성 측정2) Determination of rat liver ADH activity
쥐간 ADH 활성 측정을 위하여 체중 약 260g 전후의 스프래그-다우리(Sprague-Dawley)계 수컷을 이용하였다. 쥐를 단두한 후 복부를 절개하여 간을 적출하였다. 적출된 간에 적출 장기 중량(0.6g)의 10배에 해당하는 10mM 트리스 완충액(pH 7.4)를 첨가하고, 균질화하고 700×g에서 10분간 원심분리하여 핵분획을 제거한 뒤, 상등액은 10,000×g에서 20분간 원심분리한 후 다시 상등액을 105,000×g에서 60분간 초원심분리하였다. 초 원심분리된 상등액인 세포질 분획을 ADH 효소액으로 사용하였다(Kim and park, 1997).Sprague-Dawley males weighing about 260 g were used to measure ADH activity in rat liver. After the rats were guillotine, the abdomen was excised to remove the liver. After removal of the nuclear fraction by adding 10 mM Tris buffer (pH 7.4) equal to 10 times the organ weight (0.6 g) of the extracted liver, homogenizing and centrifuging at 700 × g for 10 minutes, the supernatant was collected at 10,000 × g. After centrifugation for 20 minutes, the supernatant was ultracentrifuged at 105,000 × g for 60 minutes. The cytosolic fraction, the supercentrifuged supernatant, was used as the ADH enzyme solution (Kim and park, 1997).
조제된 쥐간 ADH의 활성 측정은 1.0 mM NAD+, 5 mM 에탄올을 함유하는 33mM 소디움 포스페이트 완충액(pH 8.0)을 UV 큐베트에 넣은 뒤 쥐 간세포질 분획 0.05㎖를 가하여 총부피가 1㎖가 되도록 대조시험으로 하였다. 추출물 시료에 대한 쥐간 ADH의 활성은 이스트 ADH의 활성측정법과 동일하게 수행하였다.The activity of the prepared rat liver ADH was measured by adding 33 mM sodium phosphate buffer (pH 8.0) containing 1.0 mM NAD + and 5 mM ethanol to UV cuvettes and adding 0.05 ml of rat hepatocellular fraction to a total volume of 1 ml. It was a test. The activity of rat liver ADH on the extract sample was performed in the same manner as in the assay of yeast ADH activity.
2. 결과 및 고찰2. Results and Discussion
표2. 수득된 약용 식물의 40% 에틸알콜 추출물의 상대적인 ADH 활성(%)Table 2. Relative ADH activity (%) of 40% ethyl alcohol extract of medicinal plants obtained
표 2는 5종의 한약재 추출시료 모두 이스트 ADH에 대한 저해활성을 나타내었다. 표 2를 참조하면, 그 활성의 크기는 감초≥갈화≥오리목≥귤피≥지구병의 순으로 저해활성 특성이 나타났으며 쥐간 시토졸(cytosol)의 ADH에 대하여도 유사한 경향으로 저해활성이 나타났다. 특히 갈화, 오리목, 감초는 이스트 ADH에 대하여 90% 이상 저해하는 강한 활성이 나타났으며 이러한 결과들은 이전의 연구결과(Lee and Lee, 1999; Moon et al., 2004)와 아주 유사한 ADH에 대한 저해활성을 나타내는 결과이다.Table 2 shows the inhibitory activity against yeast ADH in all five herbal extracts. Referring to Table 2, the magnitude of the activity was found to be in the order of licorice ≥ browning ≥ mallard ≥ tangerine ≥ earth disease in the order of inhibitory activity in a similar trend for ADH of rat liver cytosol (cytosol). In particular, browning, alder, and licorice showed a strong activity that inhibited more than 90% of yeast ADH. These results showed that ADH was very similar to previous studies (Lee and Lee, 1999; Moon et al., 2004). Results indicate activity.
표 3. 숙취해소음료의 상대적인 ADH 활성(%)Table 3. Relative ADH activity (%) of hangover beverage
표 3은 본 연구에서 조제한 숙취음료 해주가 및 타회사 숙취음료를 이용하여 이스트 ADH와 쥐간 시트졸 분획의 ADH에 대한 저해활성을 측정하여 나타내었다. 표 3을 참조하면, 해주가가 A사 제품과 유사한 ADH 저해활성을 나타내었으며, 이에 반하여 C사 제품은 시험관 내에서 그대지 높지 않은 ADH 저해활성을 나타내었다. Table 3 shows the inhibitory activity against ADH of yeast ADH and rat liver citsol fractions using the hangover and other company's hangover prepared in this study. Referring to Table 3, Haeda showed similar ADH inhibitory activity as that of Company A, whereas Company C exhibited not very high ADH inhibitory activity in vitro.
시험관(in vitro) 실험인 이스트 ADH에 대해 강한 저해활성을 보인 추출물 및 숙취해소음료는 좀 더 생체내(in vivo) 상황에 가까운 쥐간 세포질 분획에 대해서도 그 활성은 약간 떨어졌지만 공통적으로 저해활성을 나타내는 결과가 나타났기 때문에 이전에 제시한 (Lee and Lee, 1999) 순수 분리된 효소에 대한 활성 검사결과를 생체에 대한 활성을 추정하는데 이용할 수 있을 것이라는 생각을 뒷받침하는 결과라 생각된다. 그리고 아울러 명확한 유효성분이나 작용기전이 규명되지 않은 상태로 한방과 민간에서 간질환의 치료와 간 보호에 사용되어 왔던 이들 약재들이 ADH에 대하여 저해활성을 나타낸 결과들은 본 연구에 사용한 약제 이외의 간 질환 치료 및 보호 약물로 사용하는 약제들 또한 ADH의 저해활성을 나타낼 수 있다는 가능성을 추정할 수 있다.Extracts and hangover beverages that showed strong inhibitory activity against yeast ADH, in vitro experiments, showed a slight decrease in the cytoplasmic fraction of rat liver, which is more in vivo. The results suggest that (Lee and Lee, 1999) support the idea that the activity test results for purely isolated enzymes can be used to estimate biological activity. In addition, the results of these drugs, which have been used for the treatment of liver disease and the protection of liver in oriental medicine and folk medicine, without clear active ingredients or mechanisms of action, showed inhibitory activity against ADH. It can be estimated that drugs used as therapeutic and protective drugs may also exhibit inhibitory activity of ADH.
시험예2Test Example 2 : : DPPHDPPH 를 이용한 전자 Electron 공여능Donation ability 측정 Measure
1. 실험방법1. Experimental method
각 시료에 대한 항산화 활성 측정은 히드라질(hydrazyl)에 불안정한 상태의 질소원자가 수소원자를 받아들이는 성질을 이용해 항산화물질과 반응하여 자체의 정색성을 소실하는 DPPH((1,1-diphenyl-2- picrylhydrazyl, Sigma Co., St. Louis, MO, USA)의 특성을 이용한 방법으로 이전의 연구방법(Blois, 1958; Lee et al., 2002: Moon et al., 2004)을 변형하여 측정하였다. 조제된 에탄올성 1.5×10-4 M DPPH 990㎕를 각각의 농도별 추출물 10㎕와 함께 와동(vortex)하고 3분 후 517㎚에서 흡광도를 측정하였다. 대조군은 시료대신 시료를 녹이는데 사용한 용매를 사용하였으며, DPPH의 전자 공여능(electron donating ability, EDA, %)는 다음식으로 계산하였다.Antioxidant activity of each sample was measured by DPPH ((1,1-diphenyl-2-), which loses its color by reacting with an antioxidant using nitrogen accepting hydrogen atoms in an unstable state of hydrazyl. A method using the characteristics of picrylhydrazyl, Sigma Co., St. Louis, MO, USA) was measured by modifying the previous method (Blois, 1958; Lee et al., 2002: Moon et al., 2004). 990 μl of ethanol 1.5 × 10 −4 M DPPH was vortexed with 10 μl of extract for each concentration, and the absorbance was measured at 517 nm after 3 minutes, using the solvent used to dissolve the sample instead of the sample. The electron donating ability (EDA,%) of DPPH was calculated by the following equation.
EDA(%)= (B-A)/B×100EDA (%) = (B-A) / B × 100
A: 517㎚에서 시료의 흡광도A: absorbance of the sample at 517 nm
B: 517㎚에서 대조구의 흡광도B: absorbance of the control at 517 nm
각 시료의 농도 및 양에 따라 얻어진 EDA(%)는 다시 농도와 소거율의 상관관계에 의해 얻어진 방정식으로부터 시료 첨가 후 3분 때에 DPPH의 농도가 50% 감소하는데 필요한 시료 추출물의 농도(RC50)를 산출하였다. 또한 비교구로서 지용성 항산화제인 (+)-α-토코페롤(비타민 E, Sigma Co., St. Louis, MO, USA)을 이용하여 항산화 활성을 비교하였다.The concentration of EDA (%) is the sample extract necessary for the DPPH concentration of 50% reduction in the
2. 평가기준2. Evaluation Criteria
일반적으로 특정물질에 대한 항산화 활성을 측정하는 방법에는 여러가지가 있으나, 그 중에서 DPPH 라디칼 소거 활성법은 비교적 간단하면서도 대량으로 측정이 가능한 방법이다. 이 물질은 라디칼을 갖는 물질 중에서 비교적 안정한 화합물로 에탄올 용액에서 보라색으로 발색된다. 그러나 항산화 활성을 갖는 물질을 만나면 항산화 활성 물질이 DPPH의 라디칼을 소거시켜 탈색되는 점을 이용하여 항산화 활성을 쉽게 측정할 수 있다. 따라서 미지의 식물 추출물의 항산화 활성과도 연관성이 매우 높은 장점을 가지고 있으며, 실제 항산화 활성과도 연관성이 높은 장점이 있다(Song et al., 2000). 즉 전자공여 작용은 활성 라디칼에 전자를 공여하여 지방질 산화를 억제시키는 척도로 사용되고 있을 뿐만 아니라 인체 내에서 활성 라디칼에 의한 질병과 노화를 억제하는 작용의 척도로도 이용되고 있다(Choi and Oh, 1985; Harman, 1987)In general, there are many methods for measuring the antioxidant activity of a specific substance. Among them, the DPPH radical scavenging activity method is relatively simple and can be measured in large quantities. This material is a relatively stable compound with radicals and develops purple in ethanol solution. However, when encountering a substance having antioxidant activity, the antioxidant activity can be easily measured by using the fact that the antioxidant active substance discolors by scavenging radicals of DPPH. Therefore, it has the advantage of being highly associated with the antioxidant activity of the unknown plant extract, and also has the advantage of being highly associated with the antioxidant activity (Song et al., 2000). In other words, the electron donating action is used not only as a measure of inhibiting lipid oxidation by donating electrons to active radicals, but also as a measure of inhibiting disease and aging caused by active radicals in the human body (Choi and Oh, 1985). Harman, 1987)
3. 결과 및 고찰3. Results and Discussion
표 4. 수득된 약용 식물, 목초액의 40% 에틸알콜 추출물 및 숙취 음료의 전자 공여능Table 4. Electronic donating ability of medicinal plants obtained, 40% ethyl alcohol extract of wood vinegar and hangover beverage
표 4는 각각의 한약재들의 추출물 시료, 타회사 및 본 연구실에서 조제한 숙취해소음료의 DPPH에 대한 소거활성을 여러농도에서 실험하고 흡광도와 소거율과의 관계식으로부터 산출된 RC50을 나타내었다. 표 4를 참조하면, 본 연구의 비교구로 사용한 (+)-α-토코페롤의 RC50은 14.7±1.5㎍/㎖로 이전의 연구결과(Lee et al., 2002)와 아주 잘 일치하였다. 연구결과를 살펴보면 갈화와 오리목에서 460.4±10.5, 24.7±0.9 ㎍/㎖의 농도에서 효과적인 활성을 나타내었으며, 특히 오리목 추출물의 RC50은 24.7±0.9 ㎍/㎖로서 (+)-α-토코페롤과 거의 유사한 농도의 우수한 유리기 소거 효과를 보였다. 이러한 결과는 이전의 연구(Lee et al., 2003)에서 오리목이 항산화 작용이 뚜렷한 10종의 디아릴헵타노이드(diarylheptanoid)를 다량 함유하고 있음을 보고한 것이 본 연구결과를 뒷받침한다. 본 연구의 감초추출물은 이전 연구((Lee et al., 2002)의 70% 메탄올 추출물보다 RC50이 2배정도 높은 낮은 항산화 활성을 나타내었다. 이러한 결과는 천연의 항산화물질이 추출용매 및 추출조건에 따른 항산화 활성이 차이가 나타난다는 결과, 즉 열수추출물이 가장 강한 황산화 활성을 나타내며, 에탄올 추출물 보다 메탄올 추출물의 항산화 활성이 높게 나타난다는 보고(Dong et al.,2004: Kim et al., 1996; Kim et al., 2004)와 유사한 경향을 나타낸 것으로 생각되며, 이러한 경향은 지구병에서도 유사한 결과가 나타날 것으로 예상된다.Table 4 shows the scavenging activity of DPPH of extract samples of different Chinese herbs, hangover quenching drinks prepared by other companies and the laboratory at various concentrations, and shows the RC 50 calculated from the relationship between absorbance and scavenging rate. Referring to Table 4, the RC 50 of (+)-α-tocopherol used as a control of the present study was 14.7 ± 1.5 μg / ml, which is in good agreement with the previous study (Lee et al., 2002). The results of the study showed effective activity at the concentrations of 460.4 ± 10.5 and 24.7 ± 0.9 ㎍ / mL in browning and alder, especially RC 50 of Alder extract was 24.7 ± 0.9 ㎍ / mL, which was almost the same as that of (+)-α-tocopherol. Similar free radical scavenging effects were observed. These results support the findings of previous studies (Lee et al., 2003) that the alders contained large amounts of 10 diarylheptanoids with significant antioxidant activity. The licorice extract of this study showed a low antioxidant activity of RC 50 which is about 2 times higher than 70% methanol extract of previous studies (Lee et al., 2002). As a result, there was a difference in antioxidant activity, that is, hot water extract showed the strongest sulfated activity, and the antioxidant activity of methanol extract was higher than that of ethanol extract (Dong et al., 2004: Kim et al., 1996; Kim et al., 2004), and the trend is expected to show similar results in the global disease.
목초액의 DPPH에 대한 RC50은 75.7±4.0㎕로서 이전의 연구결과(Jeong and Shim, 2002)보다 항산화 활성이 10배 정도 낮게 나타났는데 이는 목초액의 제조에 따른 품질이나 성분조성 또는 탄화방법, 탄화온도, 목재 중의 수분함량 및 숙성기간에 따른 영향(Alen et al., 1996; Guilled and Ibargoitia, 1999; Guilled and Ibargoitia, 1999; Ku et al., 2002; Maga and Chen, 1985; Toth and Potthast, 1984)으로 생각되어지며 숙취해소음료의 제조에 사용되는 목초액은 일정한 품질과 성분을 지닌 목초액을 사용하여야 될 것으로 생각되어진다.RC 50 of wood vinegar was 75.7 ± 4.0 μl, which was 10 times lower in antioxidant activity than previous studies (Jeong and Shim, 2002). , The effect of moisture content and maturation period in wood (Alen et al., 1996; Guilled and Ibargoitia, 1999; Guilled and Ibargoitia, 1999; Ku et al., 2002; Maga and Chen, 1985; Toth and Potthast, 1984) It is thought that the wood vinegar used in the manufacture of hangover drink should use wood vinegar with certain quality and ingredients.
숙취해소음료에 대한 DPPH-유리기 소거능의 측정 결과 본 연구에서 조제한 해주가의 RC50이 4.1±1.7 ㎕으로 가장 낮게 나타나는 가장 강한 항산화활성을 나타내었으며, A사 > B사 > C사의 순으로 항산화 활성을 나타냈다. 그러므로 본 연구에서 조제한 숙취해소음료는 음용 후 타회사 숙취해소음료가 가지는 숙취해소 작용뿐 아니라 질병 및 노화 억제의 관점으로 보는 항산화 활성도를 가지는 우수한 천연 자원의 기능성 음료로 작용하리라 생각된다.DPPH-free radical scavenging activity of hangover drink showed the highest antioxidant activity of RC 50 of Haegagaga prepared in this study, with 4.1 ± 1.7 μl. Indicated. Therefore, the hangover drink prepared in this study is expected to act as a functional drink of excellent natural resources with anti-oxidant activity from the viewpoint of disease and aging control as well as hangover action of other company's hangover drink after drinking.
시험예3Test Example 3 : 항균활성 측정: Antibacterial activity measurement
1. 실험재료1. Experimental Materials
1) 사용균주 및 배지1) Use strain and medium
추출한 시료의 항균활성 측정을 위하여 그람 양성균(gram-positive bacteria)로서 바실루스 서브틸리스(Bacillus subtilis) PM125, 마이크로코커스 루테우스(Micrococcus luteus) KCTC 1056 및 황색포도상 구균(Staphyloccus aureus) KCTC 1916와 항생제인 메티실린(Methicillin)에 대한 내성균주인 메티실린 내성 황색포도상구균(MRSA) CCARM 3561, 3115 및 3809들을 사용하였다. 그람 음성균(gram-negative bacteria)로는 대장균(Escherichia coil) D 31, 엔테로박터 에어로게네스균 (Enterobacter aerogenes) KCTC 2190, 폐렴막대균(Klebsiella pneumoniae) KCTC 2208, 녹농균(Pseudomonas aeruginosa) KCTC 2004 및 쥐티브스균(Salmonella typhimurium) KCTC 1925를 사용하였으며, 해양 세균으로는 장염 비브리오균(Vibrio parahaemolyticus) KCTC 2471을 사용하였다.For the measurement of the antimicrobial activity of the extracted samples, Bacillus subtilis PM125, Micrococcus luteus KCTC 1056 and Staphyloccus aureus KCTC 1916 and antibiotics were identified as gram-positive bacteria. Methicillin resistant Staphylococcus aureus (MRSA) CCARM 3561, 3115 and 3809, resistant strains to Methicillin were used. Gram-negative bacteria include Escherichia coil D 31, Enterobacter aerogenes KCTC 2190, Klebsiella pneumoniae KCTC 2208, Pseudomonas aeruginosa KCTC 2004 and Mouse Salmonella typhimurium KCTC 1925 was used, and marine bacterium Vibrio parahaemolyticus KCTC 2471 was used.
그람 양성 및 그람 음성균의 전배양 및 본배양을 위한 생육배지는 트립틱 소이 액체배지 (tryptic soy broth)(TSB, Sigma Co., Darmstadt, Germany)를 사용하였으며, 고체배지로는 TSB 연한천(TSB soft agar)(TSA, Sigma Co., St. Louis, MO, USA)를 사용하였다. 또한 해양세균의 전배양 및 본배양을 위한 생육배지는 1% 염화나트륨이 포함된 TSB 및 TSA를 사용하였다.The growth medium for pre-culture and main culture of Gram-positive and Gram-negative bacteria was tryptic soy broth (TSB, Sigma Co., Darmstadt, Germany), and TSB Yeonhancheon (TSB) was used as a solid medium. soft agar) (TSA, Sigma Co., St. Louis, Mo., USA). In addition, the growth medium for preculture and main culture of marine bacteria used TSB and TSA containing 1% sodium chloride.
2. 실험방법2. Experimental method
1) 추출물의 생육저해환 측정1) Measurement of growth inhibition of extract
추출물 시료의 항균활성은 이전의 연구방법(Gavidson and Parish 1989; Turner et al., 1998)의 한천배지 확산법(disc-agar plate diffusion method)을 변형하여 실시하였다. 대수증식기(mid-logarithmic phase)까지 배양된 균액을 OD570 값이 0.1(5×107 CFU/㎖)이 되도록 희석한 후 TSB (Tryptic soy broth)에 균액을 0.1㎖ 떨어뜨려 균일하게 도포하였다. 각각의 추출물 시료는 1㎎/㎖의 농도로 취하여 멸균된 탈이온수 50㎕에 녹인 후 75% 에탄올로 제균한 페이퍼 디스크(paper disc: 후막 8㎜ 직경, Avantec Toyo, Japan)에 완전히 흡수시킨 후 배지 위에 올려놓았다. 그람 양성균 및 그람 음성균은 37℃에서 12시간 배양한 후 디스크 주위에 생성된 생육억제환(clear zone)의 직경(㎜)을 측정하였으며, 해양세균인 장염 비브리오균 KCTC 2471은 30℃에서 18시간 배양한 후 생육억제환의 직경(㎜)을 측정하여 비교하였다.Antimicrobial activity of the extract sample was performed by modifying the disc-agar plate diffusion method of the previous method (Gavidson and Parish 1989; Turner et al., 1998). The fungi cultured up to the mid-logarithmic phase were diluted so that the OD 570 value was 0.1 (5 × 10 7 CFU / mL), and the solution was uniformly applied by dropping 0.1 mL of the fungus onto TSB (Tryptic soy broth). Each extract sample was taken at a concentration of 1 mg / ml, dissolved in 50 μl of sterilized deionized water, and completely absorbed into a paper disc sterilized with 75% ethanol (thickness 8 mm diameter, Avantec Toyo, Japan). Put on top. Gram-positive bacteria and Gram-negative bacteria were cultured for 12 hours at 37 ° C, and the diameter of the clear zone formed around the disc was measured (mm). Enteritis Vibrio KCTC 2471, a marine bacterium, was cultured at 30 ° C for 18 hours. After that, the diameter of the growth inhibitory rings (mm) was measured and compared.
2) 최소저해농도(Minimum inhibitory concentration, MIC)측정2) Minimum inhibitory concentration (MIC) measurement
항균력을 나타내는 추출물 시료에 대한 최소저해농도(MIC)의 측정은 96-well plate를 이용한 액체 성장 저해 시험(liquid growth inhibition assay)법(Bullet et al., 1993)으로 측정하였고, 활성측정법은 다음과 같다. 각각의 균들을 37℃의 TSB 배지에서 대수증식기(OD630=0.4, 5×107CFC/㎖)까지 배양하였다. 96-웰 플레이트(well plate)에 균배양액과 연속적으로 희석한 시료추출물을 혼합하여 37℃에서 18시간 동안 배양한 후, ELISA MQX200(Bio-Teck instrument, USA)를 이용하여 630㎚에서 탁도를 측정한 후, 균의 성장이 억제된 최소의 농도를 시험균에 대한 최소 저해농도로 정의하였다. 해양 세균에 대한 최소 저해농도의 측정은 1% NaCl이 첨가된 TSB 배지를 이용하여 25℃에서 배양한 것 외에는 다른 균주와 동일한 방법으로 측정하였다.The measurement of the minimum inhibitory concentration (MIC) of the extract samples showing the antimicrobial activity was determined by the liquid growth inhibition assay (Bullet et al., 1993) using a 96-well plate. same. Each of the bacteria was incubated in a logarithmic growth stage (OD 630 = 0.4, 5 × 10 7 CFC / ㎖) in TSB medium at 37 ℃. After mixing the culture medium and the serially diluted sample extract in a 96-well plate (well plate) and incubated for 18 hours at 37 ℃, measuring turbidity at 630nm using ELISA MQX200 (Bio-Teck instrument, USA) Afterwards, the minimum concentration at which bacterial growth was inhibited was defined as the minimum inhibitory concentration for the test bacteria. The minimum inhibitory concentration for marine bacteria was measured in the same manner as for the other strains except for incubation at 25 ° C using TSB medium containing 1% NaCl.
3. 결과 및 고찰3. Results and Discussion
1) 추출물의 생육저해환 측정1) Measurement of growth inhibition of extract
표5. 그람 양성균로서 B. 서브틸리스 PM 125, M. 루테우스 KCTC 1056 및 S. 아우레우스 KCTC 1916, MRSA CCARM 3561, 3115 및 3809에 대해 다수의 생약재의 40% 에틸알콜 추출물이 나타낸 성장 억제Table 5. Growth inhibition indicated by 40% ethyl alcohol extract of a number of herbal medicines against B. subtilis PM 125, M. luteus KCTC 1056 and S. aureus KCTC 1916, MRSA CCARM 3561, 3115 and 3809 as Gram-positive bacteria
* 약용 식물의 추출물의 농축, ㎎/㎖* Concentration of extract of medicinal plants, mg / ml
** 측정되지 않음** not measured
표 6. 그람 음성균으로서, 대장균 D31, E. 에어로게네스균 KCTC 2190, 폐렴막대균 KCTC 2208, 녹농균 KCTC 2004, 및 장염비브리오균 및 해양세균인 장염 비브리오균 KCTC 2471에 대해 다수의 생약재 40% 에틸알콜 추출액이 나타낸 성장 억제Table 6. As a Gram-negative bacterium, a number of herbal medicines 40% ethyl for E. coli D31, E. aerogenes KCTC 2190, pneumococcal KCTC 2208, Pseudomonas aeruginosa KCTC 2004, and enteritis vibrio and marine bacteria enteritis vibrio KCTC 2471 Growth Inhibition Represented by Alcohol Extracts
* 약용 식물의 추출물의 농축, ㎎/㎖* Concentration of extract of medicinal plants, mg / ml
** 측정되지 않음** not measured
표 7. 여러 가지의 미생물에 대해 목초액이 나타낸 성장 억제 Table 7. Growth Inhibition of Wood Vinegar for Various Microorganisms
* 목초액의 부피, ㎕Volume of wood vinegar, μl
** 측정되지 않음** not measured
활성화시킨 전 배양액 TSB 배지에 접종하여 세균의 대수증식까지 본배양한 후 TSA 평판배지에 균액을 접종하여 도말하고 배지의 표면 위에 1~10㎎/㎖의 농도로 5종의 생약재 추출물 시료 50㎖와 목초액 5~45㎕의 농도로서 메티실린 내성 균주인 S. 아우레우스 3종을 포함한 그람 양성균 6종, 그람 음성균 5종 및 해양세균에 대한 페이퍼 디스크 주위의 억제존의 직경(㎜)을 측정하여 그 결과를 표 5에 나타내었다.After inoculation into the activated whole culture TSB medium, and incubated until the logarithmic growth of bacteria, inoculate and spread the bacterial solution on the TSA plate medium and 50 ml of five herbal medicine extract samples at a concentration of 1 ~ 10㎎ / ㎖ on the surface of the medium and The diameter of the inhibition zone around the paper disc against 6 Gram-positive bacteria, 5 Gram-negative bacteria, and marine bacteria, including three methicillin-resistant strains, S. aureus, was measured at a concentration of 5-45 μl of wood vinegar. The results are shown in Table 5.
귤피 추출물은 1~10㎎/㎖의 모든 농도에서 12종의 균주에 대한 항균활성은 보이지 않았다(표5 및 6). 본 실험의 귤피의 항균활성에 대한 연구는 이전 연구(Cho et al., 2003; Choi et al., 2002)의 약용식물에 대한 항균성 검색에서 귤피의 메탄올 추출물의 대장균, S. 아우레우스. S. 갈리나룸에 대한 항균활성이 없음을 보고한 것과 잘 일치하며 귤피에 다량 존재하는 항균물질인 나린진(naringin)의 MIC가 1㎎/㎖이상이라는 연구결과(Han and You, 1988)와 유사한 경향을 나타내고 있다.The tangerine extract did not show antimicrobial activity against 12 strains at all concentrations of 1-10 mg / ml (Tables 5 and 6). A study on the antimicrobial activity of tangerine in this experiment was conducted in the previous study (Cho et al., 2003; Choi et al., 2002). This is in good agreement with the report of no antimicrobial activity against S. gallinarum and similar to the results of studies showing that the MIC of naringin, a large amount of antimicrobial substance present in tangerines, is greater than 1 mg / ml (Han and You, 1988) Indicates.
표 5 내지 6 및 도1에 나타난 지구병 추출물에 대한 항균활성은 1㎎/㎖의 농도에서 실험한 모든 균주에 대해서는 항균활성을 나타내지 않았다. 5㎎/㎖의 농도에서는 MRSA CCARM 3115에서 10㎜의 생육억제환이 형성되었으나, 이외의 균주에 대해서는 항균활성이 관찰되지 않았다. 10㎎/㎖의 농도에서는 MRAS CCARM 3809에 대해서 10㎜의 생육억제환이 형성되었다. 그러나 이외의 9종의 균주에 대해서는 향균활성이 관찰되지 않았다.The antimicrobial activity against the earth disease extract shown in Tables 5 to 6 and FIG. 1 did not show antimicrobial activity against all strains tested at a concentration of 1 mg / ml. At a concentration of 5 mg / ml, growth inhibition ring of 10 mm was formed in MRSA CCARM 3115, but antimicrobial activity was not observed in other strains. At a concentration of 10 mg / ml, 10 mm growth inhibition ring was formed for MRAS CCARM 3809. However, antimicrobial activity was not observed for the other nine strains.
표 5, 6, 도1 및 도 2에 나타낸 갈화 추출물에 대한 항균활성 결과는 1㎎/㎖의 농도에서는 12종의 모든 균주에 대해서는 항균활성을 나타내지 않았다. 이러한 결과는 이전의 연구(Shin et al., 1997)에서 갈화의 75% 에탄올 추출물의 경우 1.3㎎/㎖의 농도에서 9종의 시험균주에 대해 전혀 항균활성이 관찰되지 않은 것과 유사한 결과이다. 갈화 추출물의 5㎎/㎖의 농도의 경우 MRAS CCARM 3809와 3115에서 각각 12㎜, 12㎜의 생육억제환을 형성하는 항균활성을 나타냈으며, 이외의 균주에 대한 항균활성은 관찰되지 않았다. 10㎎/㎖의 농도에서는 MRAS CCARM 3809와 3115에 대해 각각 15㎜, 14㎜의 생육억제환이 형성되어 농도가 증가할수록 항균활성도 증가함을 알 수 있었고, 해양세균인 장염 비브리오균 KCTC 2471에 대해 11㎜의 항균활성을 나타내었다(도2).The antimicrobial activity of the browning extracts shown in Tables 5, 6, 1 and 2 did not show antimicrobial activity against all 12 strains at a concentration of 1 mg / ml. This result is similar to the previous study (Shin et al., 1997) where no antimicrobial activity was observed for 9 test strains at a concentration of 1.3 mg / ml for 75% ethanol extract of browning. In the case of the concentration of 5 mg / ㎖ of the gallium extract showed an antimicrobial activity to form a growth inhibitory ring of 12 mm, 12 mm in MRAS CCARM 3809 and 3115, respectively, no antimicrobial activity was observed for other strains. At a concentration of 10 mg / ml, growth inhibition rings of 15 mm and 14 mm were formed for MRAS CCARM 3809 and 3115, respectively, and the antimicrobial activity increased as the concentration increased, and it was 11 for marine bacterium Vibrio KCTC 2471. It showed the antimicrobial activity of mm (Fig. 2).
감초 추출물은 1㎎/㎖의 농도에서는 항균활성이 관찰되지 않았다(표5 및 6). 5㎎/㎖의 농도에서는 MRAS CCARM 3115, 3809 및 3561에서 각각 13㎜, 13㎜ 및 11㎜의 생육억제환을 형성하는 항균활성을 나타내었으며, 또한 해양세균인 장염 비브리오균 KCTC 2471에 대해 12㎜의 항균활성을 나타내었다(표 5와 6). 10㎎/㎖의 농도에서 감초추출물은 그람 양성균인 바실루스 서브틸리스 PM 125에 대해 10㎜의 생육억제환을, MRSA CCARM 3115, 3809 및 3561에 대해서 각각 16, 16 및 14㎜의 생육억제환을 형성하였으며(도1과 표7), 장염 비브리오균 KCTC 2471에 대해 12㎜의 생육억제환을 형성하는 항균활성을 나타내었다(도 2와 표6). 본 연구결과에서 나타나듯이 감초 추출물은 비교적 그람 양성균, 음성균 및 해양세균에 대해 비교적 강한 항균활성을 나타내었는데, 이전의 감초의 75% 에탄올 추출물에서 항균활성을 나타내는 리퀴리티게닌(liguiritigenin)이 동정됨과 아울러 다양한 균주에 대해 폭넓은 항균활성이 관찰되었다는 보고(Ahn et al., 1998; Lee et al., 2002; Shin et al., 1994)와 유사한 결과이다. 그러나 이전의 연구(Cai et al., 2002)에 의하면 감초의 열수 및 에탄올 추출물이 S.아우레우스와 대장균 0157:H7에 대하여 200㎎/㎖에 생육억제환을 형성함을 보고하여 본 연구결과보다 강력한 항균활성을 보고하였는데, 이는 본 실험과의 추출조건, 방법 및 균종의 차이에 의해 기인된 것으로 생각되어 진다.Licorice extract was not observed antimicrobial activity at a concentration of 1 mg / ㎖ (Tables 5 and 6). At 5 mg / ml, MRAS CCARM 3115, 3809, and 3561 showed antimicrobial activity forming growth inhibitory rings of 13 mm, 13 mm, and 11 mm, respectively, and 12 mm against marine bacteria enteritis Vibrio KCTC 2471. It showed the antimicrobial activity of (Table 5 and 6). At the concentration of 10 mg / ml, licorice extract showed growth inhibition ring of 10 mm for gram-positive bacillus subtilis PM 125 and growth inhibition ring of 16, 16 and 14 mm for MRSA CCARM 3115, 3809 and 3561, respectively. 1 and Table 7, and showed an antimicrobial activity forming a growth inhibition ring of 12 mm against enteritis Vibrio KCTC 2471 (Fig. 2 and Table 6). As shown in this study, licorice extract showed relatively strong antimicrobial activity against Gram-positive bacteria, negative bacteria and marine bacteria. Liguiritigenin was identified from 75% ethanol extract of licorice. In addition, it is similar to the report that a wide range of antimicrobial activity was observed for various strains (Ahn et al., 1998; Lee et al., 2002; Shin et al., 1994). However, previous studies (Cai et al., 2002) reported that hot water and ethanol extract of licorice formed growth inhibitory rings at 200 mg / ml against S. aureus and Escherichia coli 0157: H7. Stronger antimicrobial activity was reported, which is thought to be due to differences in the extraction conditions, methods and species.
생육저해환 측정을 통한 항균활성 실험결과 가장 강한 활성을 나타낸 오리목 추출물에 대한 항균활성 결과는 표6과 7 및 도 1과 2에서 나타내었다. 1㎎/㎖의 농도에서 MRSA CCARM 3115와 3809 및 3561에 대해서 15, 12, 10㎜의 생육억제환을 형성하였다. 5㎎/㎖의 농도에서 오리목 추출물은 그람 양성균인 M.루테우스 KCTC 1056에 대해서 10㎜의 생육억제환을 형성하였으며, MRAS CCARM 3115, 3809 및 3561에 대해서 각각 21, 19, 12㎜의 생육억제환을 형성하였다. 그람 음성균인 대장균 D 31에 5㎎/㎖의 농도에서 12㎜의 생육억제환을 형성하였으며, 해양세균인 장염 비브리오균 KCTC 2471에 대해 10㎜의 항균활성을 나타내었다. 10㎎/㎖의 농도에서는 그람 양성균에 대한 항균활성으로 바실루스 서브틸리스 PM 125 및 M. 루테우스 KCTC 1056에 대해서 각각 10, 14㎜의 생육억제환을 형성하는 항균활성이 관찰되었으며, MRAS CCARM 3115, 3809 및 3561에 대해서 각각 24, 20, 15㎜의 생육억제환을 형성하는 강한 항균활성이 관찰되었다(도1). 또한 10㎎/㎖의 농도로서 그람 음성균에 대한 항균활성은 대장균 D 31 및 K.뉴모니아 KCTC 2208에 대하여 각각 16, 10㎜의 생육억제환을 형성하였고, 해양세균인 장염비브리오균 KCTC2471에 대해 12㎜의 항균활성을 나타내었다(도2). 이렇게 오리목이 강한 항균활성을 나타냄에도 불구하고 현재까지 오리목이 나나태는 항균활성에 대한 결과보고는 전무한 상태이다. 그러므로 본 연구에서 나타낸 연구결과들은 오리목이 천연 항균성 제제개발을 위한 좋은 소재가 됨을 제시한다.The antimicrobial activity of the algae extract showing the strongest activity as a result of the inhibition of growth inhibition is shown in Tables 6 and 7 and FIGS. 1 and 2. Growth inhibitory rings of 15, 12 and 10 mm were formed for MRSA CCARM 3115, 3809 and 3561 at a concentration of 1 mg / ml. At the concentration of 5 mg / mL, the algae extract formed a 10 mm growth inhibitory ring against the Gram-positive bacteria M. luteus KCTC 1056, and 21, 19, and 12 mm growth inhibition for MRAS CCARM 3115, 3809, and 3561, respectively. A ring was formed. The growth inhibitory ring of 12 mm was formed in the Gram-negative bacterium Escherichia coli D 31 at a concentration of 5 mg / ml, and had an antibacterial activity of 10 mm against the marine bacterium enteritis Vibrio KCTC 2471. At 10 mg / ml, antimicrobial activity against Bacillus subtilis PM 125 and M. luteus KCTC 1056 was observed as antimicrobial activity against Gram-positive bacteria. MRAS CCARM 3115 , 3809 and 3561, strong antimicrobial activity was observed to form a growth inhibitory ring of 24, 20, 15 mm, respectively (Fig. 1). In addition, the antimicrobial activity against Gram-negative bacteria at a concentration of 10 mg / ml resulted in growth inhibition rings of 16 and 10 mm, respectively, against E. coli D 31 and K. pneumoniae KCTC 2208, and against enteritis Vibrio bacteria KCTC2471. It showed an antimicrobial activity of 12 mm (Fig. 2). Despite the strong antimicrobial activity of alders, there is no report on the antimicrobial activity of algae. Therefore, the research results presented in this study suggest that alderwood is a good material for the development of natural antimicrobial agents.
목초액이 나타내는 항균활성은 표8 및 도3에 나타내었다. 목초액은 대장균 D 31에 대해서 35와 45㎕에서 각각 13 및 16㎜의 생육억제환을 형성하였으며, 해양세균인 장염비브리오균 KTTC 2471에 대해서는 15㎕에서 9㎜의 생육억제환을 형성하였으며, 그 양이 증가할수록 항균활성도 증가하였다. 하지만 이전의 연구결과 (Lee et al., 2004)와 비교하여 보면 본 연구에서 실험한 목초액의 항균활성이 이전의 연구결과보다 낮은 활성을 나타내었는데, 이는 본 연구결과에서 목초액의 앞에서 고찰한 항산화 활성이 낮게 나타난 것과 유사한 결과라 생각된다.The antimicrobial activity of wood vinegar is shown in Table 8 and FIG. Wood grass liquor formed 13 and 16 mm growth inhibitory rings at 35 and 45 μl against
숙취해소음료 조제를 위해 사용된 약재들에 대한 항균활성을 종합적으로 살펴보면, 본 연구에 사용한 약재들의 항균활성은 그람 음성균과 양성균에 대하여 넓은 범위의 항균활성을 나타내었으며, 그람 음성균보다 오히려 그람 양성균에 대하여 오히려 강한 항균활성을 나타내었다. 그리고 특이적으로 페니실린의 대체 항생제로 개발되었던 메티실린에 대하여 내성을 지닌 S.아우레우스에 대해 강한 항균활성을 나타낸 결과로 미루어 보아 앞으로 항생제 내성균주에 대한 강력한 항생제 개발을 위하여 천연의 한약제제가 유용한 자원으로 활용가능성을 제시하는 자료가 될 것이다. 또한 최근 생활수준의 경제적 향상과 선지화에 따른 합성품의 기피현상이 두드러지고 있는 시점에서 일반적으로 음료제조에 사용되는 합성보존료인 안식향산나트륨(sodium benzonate)를 첨가하지 않은 천연제제로 이루어진 음료개발에 유용한 자료가 될 것이라고 생각된다.Looking at the antimicrobial activity of the medicinal herbs used for the preparation of hangover, the antimicrobial activity of the medicinal herbs used in this study showed a wide range of antimicrobial activity against gram-negative and positive bacteria. Rather, it showed strong antimicrobial activity. In addition, as a result of showing strong antimicrobial activity against S. aureus resistant to methicillin, which was developed as an alternative antibiotic for penicillin, natural herbal medicines are useful for developing strong antibiotics against antibiotic resistant strains. It will be a resource that suggests availability as a resource. It is also useful for the development of beverages made of natural preparations without the addition of sodium benzoate, which is a synthetic preservative generally used in the manufacture of beverages, at a time when the retardation phenomenon of synthetic products has become prominent due to the economic improvement and advancement of living standards. I think it will be material.
시험예4Test Example 4 : : 용혈활성Hemolytic activity (( HemolysisHemolysis ) 측정) Measure
용혈활성을 측정하기 위해서 인간과 쥐의 적혈구를 사용하였다(Park et al., 1996). 신선환 적혈구를 150mM NaCl을 포함한 50mM 포스페이트 완충액(pH 7.4)으로 세정하여 최정 적혈구의 농도를 5%(v/v)가 되도록 조정하였다. 적혈구 용액과 연속적으로 추출물 시료를 넣어 37℃에서 1시간 배양 후, 원심분리(8,000×g, 10min)를 행하였다. 그 상층액을 ELISA MQX200을 이용하여 450㎚에서 측정하였다. 적혈구에 추출물 시료가 포함되지 않는 것을 0%(A)라 하고, 1% 트리톤(Triton) X-100을 넣었을 때의 흡광도를 100%(B)로 정의하여, 추출 시료를 첨가했을 때 나타나는 상대적인 흡광도(C)로부터 용혈활성%를 계산하였다.Human and rat red blood cells were used to measure hemolytic activity (Park et al., 1996). Fresh ring erythrocytes were washed with 50 mM phosphate buffer (pH 7.4) containing 150 mM NaCl to adjust the concentration of the final erythrocytes to 5% (v / v). The erythrocyte solution and the extract sample were continuously added, followed by incubation at 37 ° C. for 1 hour, followed by centrifugation (8,000 × g, 10 min). The supernatant was measured at 450 nm using ELISA MQX200. The relative absorbance at the time of addition of the extracted sample was defined as 0% (A) and the absorbance when 1% Triton X-100 was added as 100% (B) when the red blood cells did not contain the extract sample. The hemolytic activity% was calculated from (C).
용혈활성(%)=(C-A/B-A)×100Hemolytic activity (%) = (C-A / B-A) × 100
이상의 결과들을 종합하여 보면 본 연구에서 조제한 숙취해소음료는 생체내에서의 ADH 저해 활성이 뛰어날 뿐만 아니라 아울러 강력한 항산화 활성을 지닌 숙취해소음료가 될 것으로 생각되어진다. Taken together, the hangover drink prepared in this study is not only excellent in ADH inhibitory activity in vivo, but also a hangover drink with strong antioxidant activity.
본 발명의 숙취해소음료 조성물은 알코올 탈수소효소의 활성을 저해함으로써 알코올의 산화물질인 아세트알데히드의 생성을 억제시켜 간보호 효과 또는 숙취현상을 억제할 수 있는 효과를 구현할 수 있다.Hangover beverage composition of the present invention can implement the effect of inhibiting the liver protection effect or hangover phenomenon by inhibiting the production of acetaldehyde which is an oxide of alcohol by inhibiting the activity of alcohol dehydrogenase.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070057015A KR20080109116A (en) | 2007-06-12 | 2007-06-12 | Beverage for relieving hangover and manufacturing method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070057015A KR20080109116A (en) | 2007-06-12 | 2007-06-12 | Beverage for relieving hangover and manufacturing method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20080109116A true KR20080109116A (en) | 2008-12-17 |
Family
ID=40368472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020070057015A KR20080109116A (en) | 2007-06-12 | 2007-06-12 | Beverage for relieving hangover and manufacturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20080109116A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101451952B1 (en) * | 2012-12-28 | 2014-10-21 | 신봉기 | Composition and food for treating hangover containing hiliscus syriacus |
WO2016099043A1 (en) * | 2014-12-17 | 2016-06-23 | 주식회사 블루텍 | Drink composition for hangover relief and liver function improvement |
-
2007
- 2007-06-12 KR KR1020070057015A patent/KR20080109116A/en not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101451952B1 (en) * | 2012-12-28 | 2014-10-21 | 신봉기 | Composition and food for treating hangover containing hiliscus syriacus |
WO2016099043A1 (en) * | 2014-12-17 | 2016-06-23 | 주식회사 블루텍 | Drink composition for hangover relief and liver function improvement |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rupasinghe et al. | The potential health benefits of haskap (Lonicera caerulea L.): Role of cyanidin-3-O-glucoside | |
Sagbo et al. | Antioxidant, antibacterial and phytochemical properties of two medicinal plants against the wound infecting bacteria | |
JP2024010025A (en) | Compositions, methods and medical compositions for treating liver and maintaining health of liver | |
Pardhi et al. | Anti-microbial, anti-oxidant and anthelmintic activity of crude extract of Solanum xanthocarpum | |
Pérez et al. | Chemistry of natural antioxidants and studies performed with different plants collected in Mexico | |
Pareek et al. | Indian gooseberry (emblica officinalis gaertn.) | |
CN109568538B (en) | Composition for relieving hangover comprising Silybum marianum, Curcuma longa, Glycyrrhiza glabra and Cassia tora seed | |
Khalid et al. | Phenolic Profile and Biological Properties of Momordica charantia' | |
Nanasombat et al. | Evaluation of antidiabetic, antioxidant and other phytochemical properties of Thai fruits, vegetables and some local food plants | |
Akbar et al. | Glycyrrhiza glabra L.(Fabaceae/Leguminosae) (Syns.: G. glandulifera Waldst. & Kit.; G. hirsuta Pall.; G. pallida Boiss. & Noe; G. violacea Boiss. & Noe) | |
Kaimal et al. | Hypolipidaemic and antioxidant effects of fruits of Musa AAA (Chenkadali) in alloxan induced diabetic rats | |
Kolanos et al. | German chamomile | |
Saraswathi et al. | Assessment on in vitro medicinal properties and chemical composition analysis of Solanum virginianum dried fruits | |
Rangarajan et al. | Traditional fruits of South India: Bioactive components and their potential health implications in chronic diseases | |
KR20220104575A (en) | Composition for improving inflammation and improving energy and manufacturing method | |
Jagadeesan et al. | Antioxidant and free radical scavenging activities of common wild greens from Tiruvallur District of Tamil Nadu, India | |
Singh et al. | Exploring the multifaceted potential of chlorogenic acid: Journey from nutraceutical to nanomedicine | |
Omoregie et al. | In vitro antioxidant activity and the effect of methanolic extracts of some local plants on nutritionally stressed rats | |
KR20080109116A (en) | Beverage for relieving hangover and manufacturing method thereof | |
Djeussi et al. | Antioxidant activities of methanol extracts of thirteen Cameroonian antibacterial dietary plants | |
KR20150088223A (en) | Compositions for preventing or improving of alcoholic liver disease, or reducing alcoholic hangup comprising Rosa rugosa extracts | |
Ćilerdžić et al. | Do Ganoderma lucidum and Salvia officinalis extracts exhibit synergistic antioxidant and antineurodegenerative effects? | |
KR20090101600A (en) | Composition of matter having plant extracts to improve atopic dermatitis | |
KR101201148B1 (en) | Composition comprising extracts of Cedrela sinensis for anti-cancer activity | |
KR20170003153A (en) | A composition for the prevention and treatment of respiratory organ disease comprising the fractions of Asparagus cochinchinensis as an active ingredien |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |